To offset the negative impact of dysfunctional neuroprotective Tregs in ALS patients, two clinical trials with autologous infusions of expanded Tregs combined with subcutaneous low-dose IL-2 were carried out (4, 5). Here, IL2 is linked to amyotrophic lateral sclerosis.